Industry News
Nobelpharma signs a license agreement for ProBioGen’s vaccine manufacturing platform AGE1.CR.pIX
Nobelpharma will use ProBioGen’s cell-based production platform AGE1.CR.pIX to develop their lead vaccine
Nobelpharma will use ProBioGen’s cell-based production platform AGE1.CR.pIX to develop their lead vaccine
Earlier work has already confirmed the versatility and benefit of ProBioGen’s vaccine development platform
Afucosylation can enable more precise assessment of allergic sensitization